Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis
- PMID: 18803606
- DOI: 10.1111/j.1365-3083.2008.02171.x
Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis
Abstract
T-cell mediated immune responses are key determinants to the natural course of infection caused by intracellular parasites such as Leishmania. Thus, T-cell activating proteins of these microbes continue to generate active interest particularly in view of their possible role in the design and development of newer and more effective vaccines. We have recently reported the presence of T-cell immunostimulatory antigens with the high-molecular-weight (MW) fractions (134-64.2 kDa) of whole Leishmania donovani antigen (strain 2001), which stimulated variable amounts of IFN-gamma, IL-12 and IL-10 in exposed immune individuals. The present study was undertaken to further evaluate these high-MW antigenic fractions (MW range >100-60 kDa) for potential protective efficacy. The high-MW region of the parasite was resolved into five antigenic fractions (Prep A-E) using continuous elution gel electrophoresis. Prior to in vivo protection studies in hamsters, these fractions were used to evaluate in vitro cellular responses in eight Leishmania-exposed individuals and treated cured hamsters. The protective efficacy of prep (A + B), C, D and E in combination with BCG was evaluated in inbred hamsters using standard immunization protocol. Proliferative responses were seen in all eight of eight exposed individuals to prep D [median stimulation index (SI): 5.2 (range 3.9-7.1)] and E [median SI: 5.6 (range 4.4-8.2)], five of eight individuals to prep B and prep C and three of eight to prep A [median SI: 0.2 (range 0.1-7.2)]. The median proliferative responses to prep D and prep E were significantly higher than to fraction prep A; (P < 0.05) but not to prep B and prep C. However, prep A-E induced equivalent levels of IFN-gamma, IL-10 and IL-12 cytokines. Fractions D and E also exhibited marked parasite inhibition in spleen (52.5% and 73.7%) and liver (65% and 80.2%) as compared with prep (A + B) (23% in spleen and 24% in liver) and prep C (38% in spleen and 24% in liver). Prep D and prep E vaccinated animals showed higher in vitro stimulatory responses (mean SI: 6.6 and 8.8) and nitric oxide (NO) induction (mean NO levels: 6.4 and 10.7 mug/ml) against whole cell extract as compared with other groups. The protection also correlated with presence of suppressed Leishmania-specific IgG levels in prep D and prep E immunized hamsters. These studies indicate the presence of immunostimulatory and protective molecules in 60-80 kDa region of L. donovani, which may be further exploited for developing a subunit vaccine.
Similar articles
-
Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.Vaccine. 2006 Apr 5;24(15):2900-9. doi: 10.1016/j.vaccine.2005.12.053. Epub 2006 Jan 17. Vaccine. 2006. PMID: 16448729
-
Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa.Vaccine. 2008 Sep 2;26(37):4813-8. doi: 10.1016/j.vaccine.2008.06.102. Epub 2008 Jul 24. Vaccine. 2008. PMID: 18656517
-
Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.J Immunol. 2011 Dec 15;187(12):6417-27. doi: 10.4049/jimmunol.1102081. Epub 2011 Nov 11. J Immunol. 2011. PMID: 22079980
-
Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis.Trends Parasitol. 2004 Nov;20(11):524-30. doi: 10.1016/j.pt.2004.08.009. Trends Parasitol. 2004. PMID: 15471704 Review.
-
Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.Curr Opin Microbiol. 2012 Aug;15(4):476-85. doi: 10.1016/j.mib.2012.05.002. Epub 2012 Jun 13. Curr Opin Microbiol. 2012. PMID: 22698479 Review.
Cited by
-
Understanding Leishmania parasites through proteomics and implications for the clinic.Expert Rev Proteomics. 2018 May;15(5):371-390. doi: 10.1080/14789450.2018.1468754. Epub 2018 May 2. Expert Rev Proteomics. 2018. PMID: 29717934 Free PMC article. Review.
-
Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.BMC Microbiol. 2010 Jun 24;10:181. doi: 10.1186/1471-2180-10-181. BMC Microbiol. 2010. PMID: 20576102 Free PMC article.
-
A review of adjuvants for Leishmania vaccine candidates.J Biomed Res. 2010 Jan;24(1):16-25. doi: 10.1016/S1674-8301(10)60004-8. J Biomed Res. 2010. PMID: 23554607 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous